AIMTC news

Latest 1 stories · newest Nov 5, 2026

AIMTC

ImmunoTech Updates on Interim Revenue and Royalty Agreements

AIM ImmunoTech reported progress on royalty generation and trial activities but emphasized the DY15 program is still in preclinical development, with Aritosman for COVID-19 in late-stage trials.

Other Nov 5, 2026 sentiment +0.20 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same AIMTC feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/AIMTC/newsSTART FREE